- Home
- DAWN
as of 12-05-2025 3:46pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 624.8M | IPO Year: | 2021 |
| Target Price: | $26.56 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.63 - $13.92 | Next Earning Date: | 11-04-2025 |
| Revenue: | $133,672,000 | Revenue Growth: | 31.11% |
| Revenue Growth (this year): | 15.51% | Revenue Growth (next year): | 49.99% |
AI-Powered DAWN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
Gen Counsel & Secretary
Avg Cost/Share
$8.91
Shares
4,319
Total Value
$38,502.59
Owned After
62,626
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$8.91
Shares
15,894
Total Value
$141,690.24
Owned After
177,165
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$8.91
Shares
3,726
Total Value
$33,216.17
Owned After
50,809
SEC Form 4
COO and CFO
Avg Cost/Share
$8.91
Shares
4,062
Total Value
$36,211.51
Owned After
294,715
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dubow Adam | DAWN | Gen Counsel & Secretary | Nov 17, 2025 | Sell | $8.91 | 4,319 | $38,502.59 | 62,626 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Nov 17, 2025 | Sell | $8.91 | 15,894 | $141,690.24 | 177,165 | |
| Merendino Lauren | DAWN | Chief Commercial Officer | Nov 17, 2025 | Sell | $8.91 | 3,726 | $33,216.17 | 50,809 | |
| York Charles N II | DAWN | COO and CFO | Nov 17, 2025 | Sell | $8.91 | 4,062 | $36,211.51 | 294,715 |
Compare DAWN vs Leading Stocks
See how DAWN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.